Advertisement
Product › Details
Mayzent
Next higher product group | siponimod (BAF312) | |
Status | 2019-03-27 registration start | |
Organisation | Novartis AG (NYSE: NVS) | |
Group | Novartis (Group) | |
Source | Novartis AG. (4/24/19). "Press Release: Novartis Starts 2019 with Strong Sales and Double Digit Core Operating Income Growth, Mayzent Launch and Alcon Spin-off, Profit Guidance Upgraded". Basel. | |
Record changed: 2023-07-10 |
Advertisement
More documents for MS DRUGS
- [1] Sanofi S.A.. (9/28/20). "Press Release: Sanofi Completes Principia Biopharma Inc. Acquisition. Principia Biopharma Inc. Is Now a Wholly Owned Subsidiary of Sanofi". Paris....
- [2] Sanofi S.A.. (8/17/20). "Press Release: Sanofi to Acquire Principia Biopharma". Paris & South San Francisco, CA....
- [3] MedDay Pharmaceuticals S.A.S.. (3/10/20). "Press Release: MedDay Reports Top-line Data from Phase III Trial »SPI2« for Treatment of Progressive Forms of Multiple Sclerosis". Paris....
- [4] Immunic, Inc.. (4/12/19). "Press Release: Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases". San Diego, CA & Martinsried....
- [5] Lonza Group AG. (2/13/19). "Press Release: Emerald Health Pharmaceuticals and Lonza Announce Agreement for Manufacturing of Novel Cannabinoid-Derived Drug Candidate". San Diego, CA & Basel....
- [6] Neurimmune AG. (11/1/18). "Press Release: Neurimmune Appoints Natascha Schill as VP Project and Alliance Management". Schlieren....
- [7] Sanofi S.A.. (11/9/17). "Press Release: Sanofi, Principia Agree to Develop Multiple Sclerosis Drug Candidate". Paris & South San Francisco, CA....
- [8] Novartis AG. (10/25/17). "Press Release: Novartis Confirms Leadership in Multiple Sclerosis (MS) with Scientific Advancements and New Data presented at ECTRIMS". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top